June 13 Preclinical Quick Takes: A*STAR's mAb against tumor-displayed antigen; plus Columbia, Genentech and more

A*STAR targets externalized antigen to kill tumor cells
The Agency for Science Technology and Research has licensed PTP4A3-targeting cancer therapy PRL3-zumab to spinout company Intra-Immu SG Pte Ltd. (Singapore). A*STAR and colleagues reported in a Nature Communications paper the mAb directs immune cells to

Read the full 442 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE